share_log

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

諾瓦瓦克斯醫藥 | 8-K：Novavax 公佈2024年第二季度財務業績和運營亮點
美股SEC公告 ·  08/08 20:09
牛牛AI助理已提取核心訊息
On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
2024年8月8日，諾瓦瓦克斯醫藥公司公佈了截至2024年6月30日的第二季度財務業績。公司宣佈該季度總營業收入爲41500萬美元，期末現金餘額11億美元。諾瓦瓦克斯已向美國FDA和EMA申請了其更新的2024-2025COVID-19疫苗的授權，並在合作協議中收到了賽諾菲安萬特的重要預付款和股權投資。公司還在爲COVID-19-流感聯合疫苗和單獨的流感疫苗的第三階段試驗做準備，預計將於2024年第四季度開始。諾瓦瓦克斯已實施成本削減計劃，總研發和銷售費用較2023年同期減少了34%。該公司預計在2024-2025注射季節開始時交付其更新的COVID-19疫苗，並已向FDA提交EUA修正申請。諾瓦瓦克斯醫藥公司2024年全年的財務指導顯示，預計總營收爲70000萬至80000萬美元，總研發和銷售費用將保持在70000萬至75000萬美元之間。
2024年8月8日，諾瓦瓦克斯醫藥公司公佈了截至2024年6月30日的第二季度財務業績。公司宣佈該季度總營業收入爲41500萬美元，期末現金餘額11億美元。諾瓦瓦克斯已向美國FDA和EMA申請了其更新的2024-2025COVID-19疫苗的授權，並在合作協議中收到了賽諾菲安萬特的重要預付款和股權投資。公司還在爲COVID-19-流感聯合疫苗和單獨的流感疫苗的第三階段試驗做準備，預計將於2024年第四季度開始。諾瓦瓦克斯已實施成本削減計劃，總研發和銷售費用較2023年同期減少了34%。該公司預計在2024-2025注射季節開始時交付其更新的COVID-19疫苗，並已向FDA提交EUA修正申請。諾瓦瓦克斯醫藥公司2024年全年的財務指導顯示，預計總營收爲70000萬至80000萬美元，總研發和銷售費用將保持在70000萬至75000萬美元之間。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。